Pre-Clinical Efficacy of Exl-111, a Trifunctional Rapid Acting Monoclonal Antibody for Allergic Disorders
Journal of Allergy and Clinical Immunology · 2026-02 · 157 (2) · AB10
DOI: 10.1016/j.jaci.2025.12.035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-02. Verfasst von Luke Pennington und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Pennington, L., Tani, T., Morris, K., & Harris, G. (2026). Pre-Clinical Efficacy of Exl-111, a Trifunctional Rapid Acting Monoclonal Antibody for Allergic Disorders. Journal of Allergy and Clinical Immunology, 157(2), AB10. https://doi.org/10.1016/j.jaci.2025.12.035
Vancouver
Pennington L, Tani T, Morris K, Harris G. Pre-Clinical Efficacy of Exl-111, a Trifunctional Rapid Acting Monoclonal Antibody for Allergic Disorders. Journal of Allergy and Clinical Immunology. 2026;157(2):AB10. doi:10.1016/j.jaci.2025.12.035
BibTeX
@article{Pennington2026,
author = {Pennington, Luke and Tani, Travis and Morris, Karen and Harris, Geoffrey},
title = {Pre-Clinical Efficacy of Exl-111, a Trifunctional Rapid Acting Monoclonal Antibody for Allergic Disorders},
journal = {Journal of Allergy and Clinical Immunology},
year = {2026},
volume = {157},
number = {2},
pages = {AB10},
doi = {10.1016/j.jaci.2025.12.035}
}
EUVIMED